News >

FDA Approval Sought for Daratumumab Plus Carfilzomib/Dexamethasone in Relapsed/Refractory Myeloma

Jason M. Broderick @jasoncology
Published: Tuesday, Feb 11, 2020

Craig Tendler, MD, Vice President, Late Development and Global Medical Affairs, Janssen Research and Development, LLC

Craig Tendler, MD

A supplemental Biologics License Application (sBLA) has been submitted to the FDA for daratumumab (Darzalex) for use in combination with carfilzomib (Kyprolis) and dexamethasone (KdD) for the treatment of patients with relapsed/refractory multiple myeloma.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication